Breast Cancer in China
Overview
Breast cancer is the most common cancer in women. Molecular subtyping — hormone-receptor and HER2 status — now personalizes every treatment decision, and early-stage disease is curable in the large majority of patients.
China’s leading breast centers integrate screening, oncoplastic surgery and precision drug therapy under one roof, with reconstruction options that restore form at the same operation as cancer removal.
Symptoms & Signs
A painless breast lump or area of thickening
Skin dimpling, redness, scaling or nipple inversion
Nipple discharge, sometimes blood-stained
A newly visible asymmetry or change in breast contour
Swollen lymph nodes in the armpit
Screening mammography frequently detects cancers before any symptom develops
Diagnosis
Mammography with digital tomosynthesis (3D) and targeted breast ultrasound
Breast MRI for dense breasts, implant evaluation or staging
Core needle biopsy with hormone-receptor, HER2 and Ki-67 testing
Genomic risk assays (e.g. 21-gene-class) guiding chemotherapy decisions in early disease
Pathology review confirming subtype and tumor extent
Genetic counseling and BRCA testing for patients with strong family history
Treatment Options
Breast-conserving lumpectomy with radiotherapy for suitable early tumors
Mastectomy with immediate reconstruction — implant or autologous (DIEP flap) — when conservation is not possible
Sentinel lymph node biopsy sparing unnecessary axillary dissection
Neoadjuvant therapy shrinking larger tumors before surgery and providing response information
Endocrine therapy for hormone-receptor-positive disease over 5-10 years
Anti-HER2 targeted therapy, chemotherapy and immunotherapy according to subtype
Advanced Technologies & Novel Drug
3D tomosynthesis and vacuum-assisted breast biopsy
Oncoplastic surgical techniques and microsurgical reconstruction
Intraoperative radiotherapy and hypofractionated whole-breast IMRT
Dual-tracer sentinel node mapping
Novel CDK4/6 inhibitors, HER2 antibody-drug conjugates and PARP inhibitors available at major centers
Hospital & Specialist
- Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS) — Beijing
- Sun Yat-sen University Cancer Center (SYSUCC) — Guangzhou
- Fudan University Shanghai Cancer Center (FUSCC) — Shanghai
- Tianjin Medical University Cancer Institute and Hospital (TMUCIH) — Tianjin
- Li Jun Ling — Medical Oncology
- Wang Xing Yuan — Medical Oncology
- Gu Lin — Breast Oncology
- Zhang Xiao Shi — Medical Oncology